Skip to Main Content
Phase COVID-NA

Biomarkers of Clinical Subtype and Treatment Response in Obsessive-Compulsive Disorder

  • Study HIC#:0803003626
  • Last Updated:07/15/2021

This study is meant to explore the neurobiological and psychological underpinnings of obsessive compulsive disorder (OCD). It consists of several parts, including a phone screen followed by some extensive interviews with staff. Research participation may then be offered in decision making tasks or different magnetic resonance (MR) scans. The volunteers being sought must be English speaking people, ages 18 to 70 years old, able to provide informed consent, in one of the following groups: without OCD (controls), with subclinical OCD symptoms (e.g. Contamination concerns) but no diagnosis, with diagnosable OCD. Economic reimbursement averages $20 per hour. Study participation requires several visits.

Interested individuals should call 203-974-7523 or toll free 1-855-OCD-YALE (1-855-623-9253).

or email: ocd.research@yale.edu

To learn more, please see our website: ocd.yale.edu

  • Age18 years - 70 years
  • GenderBoth
  • Start Date05/06/2008
  • End Date04/19/2025

Trial Purpose and Description

The purpose of this study is to explore whether non-invasive measures of neural structure, chemistry and physiology in obessive compulsive disorder predict clinical response to pharmacological treatment with serotonin reuptake inhibitors and glutamate modulating agents and to explore whether non-invasive measures of neural structure, chemistry, and physiology distinguish between clinically differentiable subtypes of obsessive-compulsive disorder.

Eligibility Criteria

All subjects - Exclusion criteria:

a.Any contraindications to undergoing an MRI scan, including having mental implants or metal fragments in the body (contraindication to MRI, fMRI, and MRS only; subjects may still participate in ERP studies)

b.Any significant neurological or medical problem that may substantially affect CNS function, including epilepsy, stroke, thyroid disease, and poorly controlled hypertension.

c.Any unstable medical condition that may render study procedures unsafe (although all study procedures are sufficiently benign and non-invasive that this is not expected to exclude a substantial number of patients

d.Any history of significant hearing loss

e.Any history of head injury with loss of consciousness for more than 30 minutes

f.Positive urine pregnancy test

g.Active use of illicit substances

h.Active alcohol abuse

i.Primary diagnosis of a psychotic disorder

j.Primary diagnosis of pervasive developmental disorder

k.Active suicidality

Subjects with OCD or OCD symptoms

Inclusion criteria

2.DSM-IV diagnosis of OCD, established by a trained clinician interview and confirmed by SCID-IV administered by trained personnel

3.Y-BOCS score of at least 16 at evaluation or at some point during treatment

Exclusion criteria

1.Past psychosurgery

2.General exclusion criteria, as summarized above

Subjects with other mood and anxiety disorders

Inclusion criteria

1. DSM-IV diagnosis of a mood or anxiety disorder other than OCD, established by a trained clinician interview and confirmed by a SCID-IV administered by trained personnel

Exclusion criteria

1.General exclusion criteria, as summarized above

2.Psychotic depression

3.Manic state

Normal control subjects

Inclusion criteria

1.No significant history of major psychiatric disorder, based on clinician interview and confirmed by SCID-IV, adapted for normal controls, administered by trained personnel

2.No history of significant or prolonged psychotropic medication

Exclusion criteria

1.Significant family history of OCD, major depression, psychotic disorder, bipolar disorder, or suicide

2. General exclusion criteria, as summarized above

Sub-Investigators

For more information about this study, contact the Help us Discover team on: